Health Safety Messages

Murray, Joan
February 2000
FoodService Director;02/15/2000, Vol. 13 Issue 2, p72
Trade Publication
Provides information on the results of the Health and Diet Survey conducted by the United States (US) Food and Drug Administration measuring dietary awareness among people in the US. Trends in perception of the relationship between diet and cardiovascular disease; Factors where the awareness of fat in the diet may be traced; Dietary practices; Consumer awareness.


Related Articles

  • Pass the Vitameatavegamin. Hensrud, Donald D. // Fortune;7/10/2000, Vol. 142 Issue 2, p310 

    Discusses the popularity and health aspects of vitamins and dietary supplements. Speculation regarding the idea that a problem must occur with a vitamin or supplement before the United States Food and Drug Administration can examine it; Health benefits and risks associated with vitamins and...

  • The great health-care misdirection. SARDI, BILL // Functional Ingredients;Nov2013, Issue 133, p38 

    In this article the author reflects on several scientifically unproven dietary and nutritional supplements which many consumers use and on strategies which the natural products industry should use to counteract the impact of misinformation about the supplements from the media. In the article he...

  • FDA considers behind-the-counter medication availability. Walker, Tracey // Managed Healthcare Executive;Jan2008, Vol. 18 Issue 1, p7 

    The article reports on the move of the U.S. Food & Drug Administration (FDA) to consider behind-the-counter (BTC) medication availability and its impact to the improvement of public health. It explores some key issues regarding eligibility, physician involvement, reimbursement, and liability. It...

  • FDA rejects green tea claim.  // Journal of Chinese Medicine;Jun2006, Issue 81, p69 

    The article reports on the decision of the U.S. Food & Drug Administration to reject a petition about health claims on green tea. The claim concerns the relationship between green tea consumption and reduced risk for cardiovascular disease. The conclusion of the agency that there was no credible...

  • What's up with high blood pressure in African-Americans? Deas, Gerald W. // New York Amsterdam News;7/30/2009, Vol. 100 Issue 31, p26 

    The article offers information on the high blood pressure that inflicted African Americans in the U.S. Data shows that not all of these Black folks responded effectively to the same blood pressure medications. BiDil is one of the newest drug approved by the Food and Drug Administration (FDA) for...

  • Clinical Practice Guidelines for Chronic Cardiovascular Disorders: A Roadmap for the Future. Antman, Elliott M.; Jessup, Mariell // JAMA: Journal of the American Medical Association;3/26/2014, Vol. 311 Issue 12, p1195 

    In this article, the authors talk about clinical practice guidelines for chronic cardiovascular diseases (CVD) in relation to the biology of the disease process and the results of randomized clinical trials (RCTs) as of March 2014. Topics discussed include RCTs on atherosclerotic CVD, RCTs as a...

  • As FDA examines health claims, CRN defends supplement effects. Johnsen, Michael // Drug Store News;3/17/2008, Vol. 40 Issue 4, p19 

    The article reports that the Council for Responsible Nutrition (CRN) has submitted comments to the Food and Drug Administration (FDA) on the three-of-four qualified and full-blown health claims in the U.S. According to CRN, the data have continued to support the link between soy protein and the...

  • FDA: Olmesartan not linked to increased CV risk in patients with diabetes.  // Cardiology Today;Aug2014, Vol. 17 Issue 8, p4 

    The article discusses the statement made by the U.S. Food and Drug Administration (FDA) that the medication called olmesartan does not have a link to increased cardiovascular risk in patients with diabetes.

  • Public hearing on interim results of CV trials.  // Reactions Weekly;Aug2014, Vol. 1513 Issue 1, p3 

    The article offers information on the Food and Drug Administration (FDA) of the U.S. that has announced a public hearing on the confidentiality of interim results of ongoing cardiovascular (CV) outcomes safety trials which were deposited to the FDA.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics